{
  "id": "6023518f1cb411341a000097",
  "type": "factoid",
  "question": "Roflumilast Cream is effective for which disease?",
  "ideal_answer": "Roflumilast Cream has been shown to be effective for psoriasis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32845114",
    "http://www.ncbi.nlm.nih.gov/pubmed/33197348",
    "http://www.ncbi.nlm.nih.gov/pubmed/27038440",
    "http://www.ncbi.nlm.nih.gov/pubmed/32668113"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical treatment of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32668113",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trial of Roflumilast Cream for Chronic Plaque Psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32668113",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32668113",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32845114",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Background: Roflumilast cream (ARQ-151) is a highly potent, selective phosphodiesterase-4 inhibitor in development for once-daily topical treatment of chronic plaque psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32845114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Roflumilast cream was safe and highly effective at doses of 0.5% and 0.15% and represents a potential novel once-daily topical therapy for the treatment of chronic plaque psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32845114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In chronic plaque psoriasis, roflumilast cream safely increased likelihood of clear or almost clear state at 6 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33197348",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "SOURCE CITATION: Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383:229-39. 32668113.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33197348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Topical treatment with cream formulations of the PDE4 inhibitors roflumilast and TAK-084 reduced inflammation, measured as a change in skin infiltrate thickness, and reduced psoriasis severity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27038440",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "psoriasis"
}